Related Topics News -

     
 Detail   |   Print    Next page > 
     
恆瑞醫藥注射用瑞康曲妥珠單抗獲美國藥監局授予孤兒藥資格認定
2025-08-06T  
《大行》美銀證券料藥明康德繼續搶佔市場份額 升目標價至123元
2025-08-05T  
恆瑞醫藥HRS-5041片獲准開展臨床試驗
2025-07-31T  
恆瑞醫藥SHR-8068注射液、阿得貝利單抗注射液、貝伐珠單抗注射液獲批臨床試驗
2025-07-31T  
《大行》野村升恆瑞醫藥評級至「買入」 目標價升至80.57元
2025-07-29T  
《市評》恆指上揚 保險股起舞 恆瑞醫藥飆兩成
2025-07-28T  
《大行》瑞銀:恆瑞醫藥全球業務擴張進展順利 目標價87.3元
2025-07-28T  
《大行》群益證券:恆瑞與GSK達創新藥授權料可顯著增厚利潤 研創新管線可獲價值重估
2025-07-28T  
《大行》高盛:中美貿易緊張局勢緩和等推動A股指數創新高 上調MSCI中國指數目標至90點
2025-07-28T  
恆瑞醫藥裂口高開近11% 與GSK達成創新藥獨家授權合作
2025-07-28T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.